Liberty All-Star Equity offers a high dividend yield, but underperforms benchmarks and has high expenses. Find out why USA is ...

Strategic cost management & diversification into high-value services have helped Alithya (ALYA:CA) maintain margins. See why I continue to rate the stock a buy.

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first ...

MongoDB's (MDB) new business remains unaffected by the macro environment, with strong new customer growth and a low market ...

SVOL's new strategy involves significant exposure to S&P 500 ETF shares and short futures contracts. Read why I downgrade the ...

ADT ( NYSE: ADT) on Monday announced a proposed sale of 56M of its common stock held by certain entities managed by affiliates of Apollo Global Management ( NYSE: APO ). The underwriters will have a ...

Stock market performance, not the economy, predicts US presidential elections with incumbent presidents based on historical ...

Allianz (ALIZY) excels with a leading P&C division, hybrid savings model, and PIMCO asset management. Read why I downgrade ...

Astec Industries' backlog continues to shrink, indicating persistent challenges. See why I retain my sell rating on ASTE ...

Richemont has outperformed luxury peers YTD, as it has maintained sales levels in a weak market. Read what prompts a Hold ...

Increased our position in Inari Medical, Inc. due to attractive valuations for a market-leading medical device company. Inari ...

Ford's earnings are complicated by Rivian's impact and EVs, but the real issues are interest rate hikes and warranty costs. See why I continue to avoid F stock.